Jump Financial LLC Takes Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Jump Financial LLC bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 24,000 shares of the biopharmaceutical company's stock, valued at approximately $1,105,000.

Several other large investors have also bought and sold shares of the stock. Assetmark Inc. boosted its position in Xenon Pharmaceuticals by 21.5% during the third quarter. Assetmark Inc. now owns 7,103 shares of the biopharmaceutical company's stock valued at $243,000 after acquiring an additional 1,258 shares during the last quarter. Moody Aldrich Partners LLC bought a new stake in Xenon Pharmaceuticals in the third quarter worth approximately $312,000. Barclays PLC lifted its stake in Xenon Pharmaceuticals by 3.7% in the third quarter. Barclays PLC now owns 9,521 shares of the biopharmaceutical company's stock valued at $324,000 after buying an additional 342 shares during the period. Advisors Asset Management Inc. grew its position in shares of Xenon Pharmaceuticals by 25.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 10,188 shares of the biopharmaceutical company's stock worth $348,000 after buying an additional 2,096 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Xenon Pharmaceuticals by 417.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,546 shares of the biopharmaceutical company's stock valued at $394,000 after acquiring an additional 6,895 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

XENE has been the subject of a number of research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, April 10th. Needham & Company LLC reissued a "buy" rating and set a $62.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, May 10th. Royal Bank of Canada reduced their target price on Xenon Pharmaceuticals from $56.00 to $55.00 and set an "outperform" rating for the company in a report on Friday, March 1st. Citigroup dropped their price target on Xenon Pharmaceuticals from $62.00 to $60.00 and set a "buy" rating on the stock in a report on Friday, May 10th. Finally, Wedbush decreased their target price on Xenon Pharmaceuticals from $51.00 to $50.00 and set an "outperform" rating for the company in a research report on Friday, May 10th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. According to MarketBeat, Xenon Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $59.11.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, EVP Sherrington Robin sold 7,137 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total value of $330,300.36. Following the completion of the sale, the executive vice president now owns 8,398 shares of the company's stock, valued at $388,659.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Xenon Pharmaceuticals news, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total value of $601,640.00. Following the transaction, the director now directly owns 2,000 shares of the company's stock, valued at approximately $92,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sherrington Robin sold 7,137 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $330,300.36. Following the sale, the executive vice president now directly owns 8,398 shares of the company's stock, valued at approximately $388,659.44. The disclosure for this sale can be found here. 5.43% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Stock Down 1.3 %

XENE traded down $0.54 during trading on Friday, reaching $39.80. 261,461 shares of the company were exchanged, compared to its average volume of 336,930. Xenon Pharmaceuticals Inc. has a 12-month low of $27.99 and a 12-month high of $50.99. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -14.69 and a beta of 1.19. The company's 50-day moving average is $42.17 and its two-hundred day moving average is $41.87.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.07. The firm had revenue of $1.00 million for the quarter. During the same period in the prior year, the business earned ($0.63) EPS. Xenon Pharmaceuticals's quarterly revenue was up .0% on a year-over-year basis. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -2.94 earnings per share for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.